| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
26,540,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Biodesix is a data-driven diagnostic solutions company utilizing technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, Co. provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. Co.'s diagnostic blood-based tests across the lung cancer continuum of care include: Nodify XL2® and Nodify CDT® tests, which assess the risk of lung cancer to help identify the appropriate treatment pathway.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
329,027 |
25,107,838 |
| Total Buy Value |
$0 |
$0 |
$465,521 |
$29,219,329 |
| Total People Bought |
0 |
0 |
1 |
7 |
| Total Buy Transactions |
0 |
0 |
9 |
25 |
| Total Shares Sold |
49,763 |
107,859 |
134,915 |
231,656 |
| Total Sell Value |
$82,840 |
$194,187 |
$229,642 |
$397,263 |
| Total People Sold |
5 |
5 |
5 |
7 |
| Total Sell Transactions |
5 |
10 |
30 |
63 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schuler Jack W |
|
• • • |
2022-12-14 |
4 |
B |
$1.65 |
$312,945 |
I/I |
189,675 |
20,309,189 |
0.01 |
- |
|
| Schuler Jack W |
|
• • • |
2022-12-13 |
4 |
B |
$1.58 |
$106,529 |
I/I |
67,402 |
20,119,514 |
0.01 |
- |
|
| Schuler Jack W |
|
• • • |
2022-12-12 |
4 |
B |
$1.48 |
$148,380 |
I/I |
100,000 |
20,052,112 |
0.01 |
- |
|
| Kennedy Lawrence T. Jr |
|
• • • |
2022-11-21 |
4 |
B |
$1.15 |
$12,500,000 |
I/I |
10,869,565 |
4,355,914 |
0.01 |
- |
|
| Schuler Jack W |
|
• • • |
2022-11-21 |
4 |
B |
$1.15 |
$10,000,000 |
I/I |
8,695,652 |
19,952,112 |
0.01 |
- |
|
| Massarany Hany |
|
• • – |
2022-11-21 |
4 |
B |
$1.15 |
$149,999 |
D/D |
130,434 |
137,934 |
0.01 |
- |
|
| Kayyem Jon Faiz |
|
• • – |
2022-11-21 |
4 |
B |
$1.15 |
$200,000 |
I/I |
173,913 |
173,913 |
0.01 |
- |
|
| Watts Charles M |
|
• • – |
2022-11-21 |
4 |
B |
$1.15 |
$50,000 |
D/D |
43,478 |
51,333 |
0.01 |
- |
|
| Hutton Scott |
President & CEO |
• • – |
2022-11-21 |
4 |
A |
$1.15 |
$75,000 |
D/D |
65,217 |
171,227 |
|
- |
|
| Okane Kieran |
Chief Commercial Officer |
• • – |
2022-11-21 |
4 |
A |
$1.15 |
$4,999 |
D/D |
4,347 |
19,531 |
|
- |
|
| Georgantas Robert William Iii |
Chief Scientific Officer |
• • – |
2022-11-21 |
4 |
A |
$1.15 |
$13,800 |
D/D |
12,000 |
38,114 |
|
- |
|
| Cowie Robin Harper |
CFO, Secy & Treasurer |
• • – |
2022-11-21 |
4 |
A |
$1.15 |
$20,000 |
D/D |
17,391 |
91,920 |
|
- |
|
| Strobeck Matthew |
|
• • – |
2022-11-21 |
4 |
B |
$1.15 |
$2,069,997 |
I/I |
1,799,997 |
2,135,076 |
0.01 |
- |
|
| Strobeck Matthew |
|
• • – |
2022-11-21 |
4 |
B |
$1.15 |
$1,000,000 |
D/D |
869,565 |
2,415,151 |
0.01 |
- |
|
| Patience John |
Chairman |
• • • |
2022-11-21 |
4 |
B |
$1.15 |
$2,000,000 |
I/I |
1,739,130 |
4,550,483 |
0.01 |
- |
|
| Siurek Ryan H |
Chief Accounting Officer |
• • – |
2022-11-21 |
4 |
A |
$1.15 |
$9,999 |
D/D |
8,695 |
23,694 |
|
- |
|
| Siurek Ryan H |
Chief Accounting Officer |
• • – |
2022-11-10 |
4 |
S |
$1.02 |
$775 |
D/D |
(762) |
14,999 |
|
- |
|
| Pestano Gary Anthony |
Chief Development Officer |
• • – |
2022-11-10 |
4 |
S |
$1.02 |
$710 |
D/D |
(698) |
92,732 |
|
- |
|
| Cowie Robin Harper |
CFO, Secy & Treasurer |
• • – |
2022-11-10 |
4 |
S |
$1.02 |
$1,611 |
D/D |
(1,583) |
74,529 |
|
- |
|
| Hutton Scott |
President & CEO |
• • – |
2022-11-10 |
4 |
S |
$1.02 |
$6,194 |
D/D |
(6,087) |
106,010 |
|
- |
|
| Georgantas Robert William Iii |
Chief Scientific Officer |
• • – |
2022-11-10 |
4 |
S |
$1.02 |
$799 |
D/D |
(785) |
26,114 |
|
- |
|
| Okane Kieran |
Chief Commercial Officer |
• • – |
2022-11-10 |
4 |
S |
$1.02 |
$766 |
D/D |
(753) |
15,184 |
|
- |
|
| Siurek Ryan H |
Chief Accounting Officer |
• • – |
2022-11-09 |
4 |
S |
$1.04 |
$1,003 |
D/D |
(963) |
15,761 |
|
- |
|
| Pestano Gary Anthony |
Chief Development Officer |
• • – |
2022-11-09 |
4 |
S |
$1.04 |
$919 |
D/D |
(882) |
93,430 |
|
- |
|
| Cowie Robin Harper |
CFO, Secy & Treasurer |
• • – |
2022-11-09 |
4 |
S |
$1.04 |
$2,083 |
D/D |
(1,999) |
76,112 |
|
- |
|
200 Records found
|
|
Page 5 of 8 |
|
|
